



ABN 11 124 426 339

Level 3, 2-4 Ross Place, South Melbourne, VIC 3205

P +61 (3) 9673 9690 F +61 (3) 9673 9699

www.purifloh.com E corporate@purifloh.com

30 April 2021

ASX Announcements

4th Floor

20 Bridge Street

Sydney, NSW, 2000

Quarterly Operations Review

Purifloh Limited ("Purifloh" or "Company") provides an update of its quarterly activities through to 30 March 2021.

In referencing the Quarterly Cashflow Report associated with this report there are two items of note within:

- I. The commencement of drawdown of the facility provided by Dilato Holdings Pty Ltd; and
- II. The substantial reduction of operating cashflow from \$810,000 (R&D and Administrative) in the December quarter to \$152,000 in the recent quarter.

The reduction in costs at this point reflect the usual development timetable of technology commercialisation as the Company moves from a broad R&D proof of technology phase towards a commercialisation focus.

The commercialisation focus is also reflected in the recent Board changes with Dr Alex Sava joining the Board, capitalising on his proven track record of cost-effective commercialising of advanced technologies.

The Company has noted a re-engineering of the relationship with Somnio Global which has also resulted in a reduction in costs, whilst retaining access to their knowledge and capabilities in Detroit. Further updates will be provided as agreed with Somnio Global.

The Company is continuing to work with Design and Industry ("D+I") which is taking the air purification units through the final design of advanced prototype and manufacture phase. D+I has provided assistance in improving certain aspects of the Company's commercial design whilst lowering the likely associated costs of production – clearly important as the Company finalises its design for manufacture. This process remains on track to achieve previously announced timelines.

The Company's project to sanitise evaporative coils in air conditioning units has already received attention as a unique solution to the transmission of airborne pathogens through air-conditioning systems. This initiative is expected to generate significant interest with more information to be provided in the forthcoming quarter.

Purifloh has been in negotiations with several partners and potential distributors of both of these products, with relevant updates to be provided as negotiations finalise.

The Company refers to its quarterly report discussing operations through to 30 September 2020 whereby it advised of plans to confirm efficacy against Covid-19 at a Good Laboratory Practice certified facility. This commentary coincided with the appointment of Dr Sava as a Technical Consultant to the Company. Dr Sava advised that the Company had already provided enough proof of the FRG's capability to destroy resistant spores, bacteria, viruses

and fungi, including the MS2 bacteriophage, as was announced to the ASX on 17 April 2018 (ASX: “*Aerosol Test Results*”). His advice was that no further costly confirmation was required at this stage.

In accordance with ASX Listing Rule 4.7C3 the Company confirms related party charges through the quarter as follows:

- \$30,251 being payment of fees to Directors.

Approved by the Board of Purifloh Limited

END

For further information:

Jon Evans (Director)
Melbourne, Australia
+ 613 9673 9673

Simon Lill (Director)
Australia
+613 9673 9673